latest
Market/Novel Tech Articles

Applied Genetic Technologies Corporation (Nasdaq: AGTC) reports interim Phase 1/2 achromatopsia study data

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a gene therapy company in Florida, has reported encouraging interim six-month data from dose-escalation cohorts of a Phase 1/2 trial in patients with achromatopsia.  According to the sponsor, interim results demonstrated “encouraging signs of biologic activity and a favorable safety profile”.  The study is listed at the US clinical […]

Read full story

Roche acquisition of Spark Therapeutics continues to build gene therapy market

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) recently announced the completion of the acquisition of the gene therapy company, following regulatory approval from government authorities. Roche’s $4.8 billion acquisition of Spark was a 64% increase from its initial $2.7 billion offer in what turned out to be a two-way […]

Read full story

NanoDimension and Novartis Venture Fund invest CHF 8 million for optogenetic retinal gene therapies

NanoDimension, a venture capital company in Lausanne, and Novartis Venture Fund in Basel, have launched a new ophthalmology company, Arctos Ltd., to develop viral vector technology for the restoration of eyesight on several ophthalmic indications.  NanoDimension has led the round of CHF 6 million while the balance of the funding will be provided by the […]

Read full story

Related Market/Novel Tech News